Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 2/20 | 0.70 |
| ▸ | AR | P10275 | 17/20 | 0.70 |
| ▸ | MAOB | P27338 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104927 | 0.90 | AGER (0.65) | AGERARMAOB | |
| SCHEMBL1094493 | 0.86 | AR (0.70) | AGERARMAOB | |
| SCHEMBL4579567 | 0.85 | AR (0.69) | AGERARMAOB | |
| SCHEMBL236736 | 0.84 | AR (0.74) | AGERARMAOB | |
| SCHEMBL15339822 | 0.84 | AGER (0.67) | AGERARMAOB | |
| SCHEMBL9190450 | 0.84 | AGER (0.71) | AGERARMAOB | |
| SCHEMBL16603992 | 0.83 | AGER (1.00) | AGERARMAOB | |
| SCHEMBL16603989 | 0.83 | AGER (1.00) | AGERARMAOB | |
| SCHEMBL1104924 | 0.82 | AR (1.00) | AGERARMAOB | |
| SCHEMBL29724610 | 0.82 | AR (1.00) | AGERARMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304727-A1 | PHOTOINITIATOR PACKAGE COMPRISING PHOSPHINE OXIDE PHOTOINITIATORS, COUMARIN-BASED SENSITIZERS AND AMINE ADDITIVES | IGM GROUP B.V. (NL) | 2025-10-02 | — | — | US | claimed |
| EP-4519376-A1 | PHOTOINITIATOR PACKAGE COMPRISING PHOSPHINE OXIDE PHOTOINITIATORS, COUMARIN-BASED SENSITIZERS AND AMINE ADDITIVES | IGM Group B.V. (NL) | 2025-03-12 | — | — | EP | claimed |
| CN-119137224-A | Photoinitiator package comprising a phosphine oxide photoinitiator, a coumarin-based sensitizer and an amine additive | IGM集团公司 | 2024-12-13 | — | — | CN | claimed |
| WO-2023214013-A1 | PHOTOINITIATOR PACKAGE COMPRISING PHOSPHINE OXIDE PHOTOINITIATORS, COUMARIN-BASED SENSITIZERS AND AMINE ADDITIVES | IGM GROUP B. V. (NL) | 2023-11-09 | — | — | WO | claimed |
| US-9127092-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2015-09-08 | — | — | US | claimed |
| US-20140187725-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2014-07-03 | — | — | US | claimed |
| US-20040106216-A1 | Method of measuring drug-metabolizing enzyme activity, method of evaluating inhibition of drug-metabolizing enzyme activity, and composition for these methods | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2004-06-03 | — | — | US | claimed |
| EP-1378751-A2 | Method of measuring drug-metabolizing enzyme activity, method of evaluating inhibition of drug-metabolizing enzyme activity, and composition for these methods | Toyo Boseki Kabushiki Kaisha (JP) | 2004-01-07 | — | — | EP | claimed |
| EP-4555025-B1 | PHOTOINITIATOR PACKAGE COMPRISING SPECIALISED BISACYLPHOSPHINE OXIDE PHOTOINITIATORS, FURTHER ACYLPHOSPHINE OXIDE PHOTOINITIATORS AND OPTICAL BRIGHTENER SENSITIZERS | IGM GROUP B V (NL) | 2026-05-13 | — | — | EP | disclosed |
| EP-4534614-B1 | PHOTOINITIATOR PACKAGE COMPRISING SPECIALISED BISACYLPHOSPHINE OXIDE PHOTOINITIATORS, FURTHER ACYLPHOSPHINE OXIDE PHOTOINITIATORS AND OPTICAL BRIGHTENER SENSITIZERS | IGM GROUP B V (NL) | 2026-04-15 | — | — | EP | disclosed |
| EP-4722303-A1 | PHOTOINITIATOR PACKAGE COMPRISING SPECIALISED BISACYLPHOSPHINE OXIDE PHOTOINITIATORS, FURTHER ACYLPHOSPHINE OXIDE PHOTOINITIATORS AND OPTICAL BRIGHTENER SENSITIZERS | IGM Group B.V. (NL) | 2026-04-08 | — | — | EP | disclosed |
| EP-4273200-B1 | PHOTOINITIATOR PACKAGE COMPRISING SPECIALISED BISACYLPHOSPHINE OXIDE PHOTOINITIATORS AND OPTICAL BRIGHTENER SENSITIZERS | IGM GROUP B V (NL) | 2026-03-25 | — | — | EP | disclosed |
| US-20260001839-A1 | IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION | NOVARTIS PHARMA AG (CH) | 2026-01-01 | — | — | US | disclosed |
| US-20250304727-A1 | PHOTOINITIATOR PACKAGE COMPRISING PHOSPHINE OXIDE PHOTOINITIATORS, COUMARIN-BASED SENSITIZERS AND AMINE ADDITIVES | IGM GROUP B.V. (NL) | 2025-10-02 | — | — | US | disclosed |
| EP-1272663-A2 | POLYMORPHISMS IN THE HUMAN CYP2B6 GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Epidauros Biotechnologie AG (DE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001059152-A9 | POLYMORPHISMS IN THE HUMAN CYP2B6 GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | EPIDAUROS BIOTECHNOLOGIE AG (DE) | 2002-08-08 | — | — | WO | disclosed |
| US-20020045620-A1 | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2002-04-18 | — | — | US | disclosed |
| WO-2002024689-A1 | ISOXAZOLIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DIABETES, HYPERLIPIDEMIA, AND ATHEROSCLEROSIS | ARYX THERAPEUTICS (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001059152-A2 | POLYMORPHISMS IN THE HUMAN CYP2B6 GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | EPIDAUROS BIOTECHNOLOGIE AG (DE) | 2001-08-16 | — | — | WO | disclosed |
| US-6207404-B1 | SUBJECTING THE CYTOCHROME P450 ENZYME AND THE COUMARIN BASED COMPOUND TO CONDITIONS WHEREBY THE CYTOCHROME P450 ENZYME CATALYZES THE CONVERSION OF THE COUMARIN BASED COMPOUND TO A FLUORESCENT PRODUCT | GENTEST CORPORATION | 2001-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001839-A1 | IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION | S1PR1, S1PR2, S1PR3 | AGER 508/4885AR 542/4885MAOB 2493/4885 |
| US-20020045620-A1 | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals | LIPA, PNLIP, PCSK9 | AGER 1856/4885AR 4159/4885MAOB 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.